CSF3 and neutropenia: This regimen was subsequently ‘accelerated’ – given every 2 weeks rather than every 3 weeks – an adaptation made possible through the use of granulocyte colony-stimulating factor, which helped to prevent chemotherapy-associated neutropenia (Citron et al, 2003).